81.19 USD
-3.09 (-3.67%)
81.19 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to MLAB. MLAB was compared to 57 industry peers in the Life Sciences Tools & Services industry. While MLAB is still in line with the averages on profitability rating, there are concerns on its financial health. MLAB has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
MLAB had negative earnings in the past year.
MLAB had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: MLAB reported negative net income in multiple years.
MLAB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
MLAB has a Return On Assets of -0.37%. This is in the better half of the industry: MLAB outperforms 66.67% of its industry peers.
With a decent Return On Equity value of -0.88%, MLAB is doing good in the industry, outperforming 68.42% of the companies in the same industry.
With a decent Return On Invested Capital value of 3.11%, MLAB is doing good in the industry, outperforming 64.91% of the companies in the same industry.
MLAB had an Average Return On Invested Capital over the past 3 years of 2.10%. This is significantly below the industry average of 14.00%.
The 3 year average ROIC (2.10%) for MLAB is below the current ROIC(3.11%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.37% | ||
| ROE | -0.88% | ||
| ROIC | 3.11% |
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
1.3 Margins
MLAB has a Operating Margin of 6.13%. This is in the better half of the industry: MLAB outperforms 61.40% of its industry peers.
In the last couple of years the Operating Margin of MLAB has grown nicely.
With an excellent Gross Margin value of 62.15%, MLAB belongs to the best of the industry, outperforming 82.46% of the companies in the same industry.
MLAB's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.13% | ||
| PM (TTM) | N/A | ||
| GM | 62.15% |
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), MLAB is destroying value.
MLAB has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MLAB has been increased compared to 5 years ago.
The debt/assets ratio for MLAB has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.33, we must say that MLAB is in the distress zone and has some risk of bankruptcy.
MLAB has a Altman-Z score of 1.33. This is in the lower half of the industry: MLAB underperforms 61.40% of its industry peers.
The Debt to FCF ratio of MLAB is 4.69, which is a neutral value as it means it would take MLAB, 4.69 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.69, MLAB is in the better half of the industry, outperforming 71.93% of the companies in the same industry.
A Debt/Equity ratio of 0.95 indicates that MLAB is somewhat dependend on debt financing.
The Debt to Equity ratio of MLAB (0.95) is worse than 78.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | 4.69 | ||
| Altman-Z | 1.33 |
ROIC/WACC0.29
WACC10.57%
2.3 Liquidity
A Current Ratio of 2.02 indicates that MLAB has no problem at all paying its short term obligations.
MLAB has a worse Current ratio (2.02) than 61.40% of its industry peers.
A Quick Ratio of 1.44 indicates that MLAB should not have too much problems paying its short term obligations.
MLAB has a Quick ratio of 1.44. This is in the lower half of the industry: MLAB underperforms 63.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.02 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
MLAB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -104.68%.
The earnings per share for MLAB have been decreasing by -39.16% on average. This is quite bad
The Revenue has been growing slightly by 7.39% in the past year.
The Revenue has been growing by 15.41% on average over the past years. This is quite good.
EPS 1Y (TTM)-104.68%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%-43.61%
Revenue 1Y (TTM)7.39%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%5.02%
3.2 Future
The Earnings Per Share is expected to grow by 231.94% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 4.49% on average over the next years.
EPS Next Y2707.43%
EPS Next 2Y382.35%
EPS Next 3Y231.94%
EPS Next 5YN/A
Revenue Next Year3.09%
Revenue Next 2Y4.17%
Revenue Next 3Y4.49%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MLAB. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 49.85, MLAB can be considered very expensive at the moment.
The rest of the industry has a similar Price/Forward Earnings ratio as MLAB.
MLAB is valuated expensively when we compare the Price/Forward Earnings ratio to 23.70, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 49.85 |
4.2 Price Multiples
MLAB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MLAB is cheaper than 87.72% of the companies in the same industry.
98.25% of the companies in the same industry are more expensive than MLAB, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.02 | ||
| EV/EBITDA | 15.56 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MLAB has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as MLAB's earnings are expected to grow with 231.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y382.35%
EPS Next 3Y231.94%
5. Dividend
5.1 Amount
MLAB has a yearly dividend return of 0.82%, which is pretty low.
MLAB's Dividend Yield is rather good when compared to the industry average which is at 0.09. MLAB pays more dividend than 100.00% of the companies in the same industry.
With a Dividend Yield of 0.82, MLAB pays less dividend than the S&P500 average, which is at 1.94.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.82% |
5.2 History
The dividend of MLAB decreases each year by -0.50%.
MLAB has been paying a dividend for at least 10 years, so it has a reliable track record.
MLAB has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)-0.5%
Div Incr Years0
Div Non Decr Years21
5.3 Sustainability
MLAB has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-222.26%
EPS Next 2Y382.35%
EPS Next 3Y231.94%
81.19
-3.09 (-3.67%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners92.73%
Inst Owner Change0%
Ins Owners5.44%
Ins Owner Change3.69%
Market Cap448.17M
Revenue(TTM)245.25M
Net Income(TTM)-1.57M
Analysts80
Price Target96.9 (19.35%)
Short Float %5.43%
Short Ratio2.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.82% |
Yearly Dividend0.64
Dividend Growth(5Y)-0.5%
DP-222.26%
Div Incr Years0
Div Non Decr Years21
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)133.29%
Min EPS beat(2)90.84%
Max EPS beat(2)175.74%
EPS beat(4)2
Avg EPS beat(4)-16.43%
Min EPS beat(4)-217.83%
Max EPS beat(4)175.74%
EPS beat(8)5
Avg EPS beat(8)416.54%
EPS beat(12)6
Avg EPS beat(12)229.18%
EPS beat(16)8
Avg EPS beat(16)167.02%
Revenue beat(2)0
Avg Revenue beat(2)-2.79%
Min Revenue beat(2)-3.63%
Max Revenue beat(2)-1.95%
Revenue beat(4)1
Avg Revenue beat(4)-0.43%
Min Revenue beat(4)-3.63%
Max Revenue beat(4)4.83%
Revenue beat(8)3
Avg Revenue beat(8)-0.19%
Revenue beat(12)3
Avg Revenue beat(12)-1.93%
Revenue beat(16)6
Avg Revenue beat(16)0.23%
PT rev (1m)0%
PT rev (3m)7.34%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.74%
EPS NY rev (1m)0%
EPS NY rev (3m)9.16%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.46%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.4%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 49.85 | ||
| P/S | 1.83 | ||
| P/FCF | 12.02 | ||
| P/OCF | 10.87 | ||
| P/B | 2.51 | ||
| P/tB | N/A | ||
| EV/EBITDA | 15.56 |
EPS(TTM)-0.27
EYN/A
EPS(NY)1.63
Fwd EY2.01%
FCF(TTM)6.76
FCFY8.32%
OCF(TTM)7.47
OCFY9.2%
SpS44.43
BVpS32.33
TBVpS-18.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.37% | ||
| ROE | -0.88% | ||
| ROCE | 3.94% | ||
| ROIC | 3.11% | ||
| ROICexc | 3.28% | ||
| ROICexgc | 14.87% | ||
| OM | 6.13% | ||
| PM (TTM) | N/A | ||
| GM | 62.15% | ||
| FCFM | 15.21% |
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
ROICexc(3y)2.32%
ROICexc(5y)2.16%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.66%
ROCE(5y)2.18%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y111.19%
ROICexc growth 5Y22.93%
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
F-Score5
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | 4.69 | ||
| Debt/EBITDA | 4.27 | ||
| Cap/Depr | 15.81% | ||
| Cap/Sales | 1.6% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 103.47% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.02 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 1.33 |
F-Score5
WACC10.57%
ROIC/WACC0.29
Cap/Depr(3y)13.3%
Cap/Depr(5y)13.77%
Cap/Sales(3y)1.71%
Cap/Sales(5y)1.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-104.68%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%-43.61%
EPS Next Y2707.43%
EPS Next 2Y382.35%
EPS Next 3Y231.94%
EPS Next 5YN/A
Revenue 1Y (TTM)7.39%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%5.02%
Revenue Next Year3.09%
Revenue Next 2Y4.17%
Revenue Next 3Y4.49%
Revenue Next 5YN/A
EBIT growth 1Y22.54%
EBIT growth 3Y55.19%
EBIT growth 5Y17.63%
EBIT Next Year177.2%
EBIT Next 3Y46.94%
EBIT Next 5YN/A
FCF growth 1Y2.55%
FCF growth 3Y6.74%
FCF growth 5Y10.67%
OCF growth 1Y3.18%
OCF growth 3Y6.07%
OCF growth 5Y11.64%
MESA LABORATORIES INC / MLAB FAQ
Can you provide the ChartMill fundamental rating for MESA LABORATORIES INC?
ChartMill assigns a fundamental rating of 4 / 10 to MLAB.
What is the valuation status of MESA LABORATORIES INC (MLAB) stock?
ChartMill assigns a valuation rating of 5 / 10 to MESA LABORATORIES INC (MLAB). This can be considered as Fairly Valued.
How profitable is MESA LABORATORIES INC (MLAB) stock?
MESA LABORATORIES INC (MLAB) has a profitability rating of 6 / 10.
What is the financial health of MESA LABORATORIES INC (MLAB) stock?
The financial health rating of MESA LABORATORIES INC (MLAB) is 3 / 10.
Can you provide the expected EPS growth for MLAB stock?
The Earnings per Share (EPS) of MESA LABORATORIES INC (MLAB) is expected to grow by 2707.43% in the next year.